At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 25 enrolled
Drug / intervention
Voxelotordrug
Likely dose
Voxelotor 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
In Brief
A Phase 4 clinical trial evaluating Voxelotor for Sickle Cell Disease and Sickle Cell Anemia. Completed, enrolled 25 participants across 10 sites.
Detailed Summary
This is a study to evaluate the effect of voxelotor on daily physical activity and sleep quality, as measured by a wrist-worn device in participants with sickle cell disease (SCD) and chronic moderate anemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease, Sickle Cell Anemia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartDec 2020
Primary CompletionSep 2022
Study CompletionSep 2022
TodayJul 2026
First PostedMay 22, 2020
Enrollment StartDec 21, 2020
Primary CompletionSep 8, 2022
Study CompletionSep 13, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.1 years ago
Interventions
Voxelotordrug
500 mg Tablet, Oral, With or Without Food